Malignant solid tumor
Conditions
Interventions
Intervention group:Autologous DC-TIL Immunotherapy
Sponsors
Gansu Provincial Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 70 years; 2. Histopathologically diagnosed as solid malignancy; 3. Availability of tumor tissueorLymph node, for maturing dendritic cells; 4. ECOG PS: 0-2; 5. Multiple organ function assessment: (without blood transfusion in 14 days) HB = 90g/L; ANC = 1.5 × 10^9/L; PLT = 80×10^9/L; BIL<1.5×upper limit of normal (ULN)and ALT <5×ULN and AST <2.5×ULN; if liver metastasis,serum Cr = 1×ULN, endogenous creatinine clearance =50ml/min (Cockcroft-Gault formula); 6. Life expectancy of greater than six months; 7. No active infection within two weeks; 8. Physician plans to use TIL treatment; 9. Consent to participate in clinical trials, Having full capacity for civil conduct.
Exclusion criteria
Exclusion criteria: 1. patients with severe liver and kidney dysfunction; 2. patients with heart failure; 3. severe pulmonary dysfunction; 4. Having an autoimmune disease, need immunosuppressive agents or hormone therapy; 5. Serious uncontrolled infection, or other serious uncontrolled concomitant disease; 6. The HIV positive; 7. Coagulation dysfunction (INR> 1.5 ULN, APTT> 1.5 ULN), with bleeding tendency or active bleeding patients; 8. active brain metastases; 9. Allergy to any interferon, interleukin 2 and other drug ingredients in the study; 10. Pregnancy or nursing females; 11. T cell-associated lymphoma and leukemia patients; 12. Physicians believe that patients are not suitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression-free survival;disease control rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival; | — |
Countries
China
Contacts
Public ContactXue Xiaodong
Gansu Provincial Hospital
Outcome results
None listed